BioWorld

Nov. 17, 2009

Failed Phase III Dims Picoplatin's SCLC Chances, Partnering Plans

Shares of Poniard Pharmaceuticals Inc. tumbled 76 percent on disappointing data from its Phase III trial of picoplatin in small-cell lung cancer, news that's certain to hamper ongoing discussions for a much-needed partnership. (BioWorld Today) Read More

Price of Not Smoking - $500M; Nabi, GSK in NicVax Partnership

CombinatoRx Still Keen on Deal with Neuromed, Despite Setback

Not JUNKing Stroke Effort, Xigen Tweaks Focus, Hunting Partners

Privately Held Addrenex Going to Partner Sciele in $29M Buyout

Success in Biofuels' Future Depends Largely on Big Oil

Interest Is Accelerating in Algae Biofuels as Fuel of the Future

Clean Energy Beats Fossil Fuels in Investments, Job Creation

FDA has Raxibacumab Questions but HGS' Shares Not Dented

Medicines Co.'s Cangrelor Shows Promise Following Earlier Miss

Genzyme's Woes Further Delay Lumizyme 4,000 L

Other News To Note

Clinic Roundup

AACR Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

Illustration of motor neuron connecting to muscle fiber

Research grants support early clinical trials of ALS treatments

BioWorld Science

The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...